Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Abbott Seeks FDA Approval of New Dosage Strengths of SIMCOR(R) (niacinextended-release/simvastatin)

By Pharmaceutical Processing | December 10, 2009

Abbott has submitted a supplemental new drug application (sNDA) to the U.S. Food andDrug Administration (FDA) for two new dosage strengths of SIMCOR, acholesterol medication. SIMCOR is a fixed-dose combination of niacinextended-release and simvastatin. Abbott is seeking FDA approval for the following new dosage strengths ofSIMCOR: 500/40 mg and 1000/40 mg (niacin extended-release/simvastatin).SIMCOR was approved by the FDA in February 2008 in the following strengths:500/20 mg, 750/20 mg and 1000/20 mg. The original FDA approval was supportedby results from the SEACOAST trial, which demonstrated efficacy and safety ofSIMCOR up to doses of 2000/40 mg daily in patients with mixed dyslipidemia andtype II hyperlipidemia. SIMCOR is a prescription medicine used along with diet in people whocannot control their cholesterol levels by diet and exercise alone. SIMCOR isapproved to lower levels of elevated total cholesterol, LDL “bad” cholesteroland triglycerides, and to raise HDL “good” cholesterol. SIMCOR is used whentreatment with simvastatin alone or niacin extended-release alone is notconsidered adequate. No additional benefit of SIMCOR on heart disease overand above that shown for niacin alone and simvastatin alone has beendemonstrated. “If approved, availability of new SIMCOR dosage strengths would be goodnews for the many patients with complex lipid disease who need additionaloptions to treat their HDL, LDL and triglycerides,” said Eugene Sun, M.D.,vice president, Global Clinical Development, Abbott.

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards